Developing and delivering new, effective and affordable drugs to patients is a complex challenge involving manufacturers, regulators, payers, providers, academic researchers and patients—all of whom are operating within a dynamic social, political and economic environment. While the approach that each stakeholder takes may be appropriate in isolation, the divergent actions within this innovation ecosystem compromise our collective ability to serve the needs of patients effectively.

MIT’s NEW Drug Development ParadIGmS (NEWDIGS) program is a unique collaborative “think and do” tank focused on enhancing the capacity of the global biomedical innovation system to reliably and sustainably deliver new, better, affordable therapeutics to the right patients faster. MIT NEWDIGS takes a systems approach to designing, evaluating and catalyzing important advancements that are so complex and cross-cutting that they cannot be addressed by a single organization or market sector.  NEWDIGS provides a pre-competitive “laboratory” for multi-stakeholder change agents to advance beyond discussions and white papers into hands-on collaborative systems re-engineering.

By bringing together diverse collaborators within a safe haven setting, and leveraging such MIT expertise as systems and financial engineering, this group informs and enables meaningful high-impact change involving the coordinated evolution of technologies, processes, policies, and people required to achieve its mission. NEWDIGS successes are built around a proven methodology of interactive multi-stakeholder, case-based simulation exercises.  The power of this collaborative innovation approach is being further enhanced through the ongoing development of next-generation linked processes and open access tools that provide increased rigor and quantification in evaluating “what if” scenarios from the perspective design options and associated implications for all stakeholders.  All activities within NEWDIGS focus on driving sustainable patient-centered innovation.

The MIT Center for Biomedical Innovation (CBI) provides program leadership and serves as the neutral intermediary for the pre-competitive activities within NEWDIGS.

CBI’s Antitrust Compliance Statement can be found here.  For questions or concerns on Antitrust, please contact Azrina Azhar.